KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, Lenvatinib clinical trials

“A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma PaTIents. PECATI”.

This study is testing a new combination of two medicines, Keytruda and Lenvatinib, for people with a type of rare cancer called thymic carcinoma or B3-thymoma that has spread. Doctors want to see if this treatment stops the cancer from growing for at least five months and if it's safe.